Sentence examples for comparator details from inspiring English sources

Information abstracted included study characteristics, participant details (eg, number of patients, eye condition, mean age and baseline comparability), intervention and comparator details (eg, source, dose, injection quality and frequency of treatment) and outcomes.

Data extracted from studies included participant and study characteristics, intervention and comparator details and results.

Population and study data comprised of country where the trial was conducted, age, disease severity, intervention and comparator details (concentration, dose, delivery mechanism), and details of any adjunct treatments given (β2 agonist or epinephrine).

The following data was extracted by one author (KL) and checked for accuracy by a second person (LP): review or study authors, date of publication, setting, study design, participant eligibility criteria, number of participants, intervention details, comparator details, type and timing of outcome measures, results and the authors' conclusion.

Extracted data included: country of the study, study design, data collection method, aim of the study, detail of participants (number, any reported demographics), study methods/intervention details, comparator details if any, length of follow up, response and/or attrition rate, context (referral from what/who to what/who), outcome measures, main results, and reported associations.

Respondents stated that other information would have been useful to complete the task, including more information about the interventions and outcomes, clarity on the comparator question and details on the size of difference considered important.

Describe the comparator in similar detail to the intervention.

61 Examples: (c) Describe the comparator in similar detail to the intervention—"Standard advice was given as for the naproxen group.

In the EudraVigilance (EV) Database, output from PRR calculated with a restricted TA comparator background was compared in detail to output from conventional authority-setting PRR calculations for four drugs: bicalutamide, abiraterone, metformin, and vildagliptin, within the TAs of prostate gland disease and type 2 diabetes mellitus.

Participants allocated to the general practice, pharmacy, or minimal intervention (comparator) groups were sent details about how to arrange their first session.

Is the comparator described in sufficient detail?